For the quarter ending 2025-09-30, ESPR made $87,309,000 in revenue. -$31,333,000 in net income. Net profit margin of -35.89%.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
| Total revenues | 87,309,000 | - | 64,995,000 | 103,424,000 |
| Cost of goods sold | 41,289,000 | - | 31,538,000 | 17,853,000 |
| Research and development | 14,131,000 | - | 12,557,000 | 12,190,000 |
| Selling, general and administrative | 41,848,000 | - | 42,996,000 | 39,456,500 |
| Total operating expenses | 97,268,000 | - | 87,091,000 | 69,499,500 |
| (loss) income from operations | -9,959,000 | 7,095,000 | -22,096,000 | 33,924,500 |
| Interest expense | 22,051,000 | 20,486,000 | 19,431,000 | 15,223,000 |
| Loss on extinguishment of debt | 0 | 0 | - | -561,000 |
| Other income, net | 677,000 | 666,000 | 1,072,000 | 1,992,000 |
| Net loss | -31,333,000 | -12,725,000 | -40,455,000 | 19,852,000 |
| Comprehensive loss | -31,333,000 | -12,725,000 | -40,455,000 | 19,852,000 |
| Net loss per common share - basic (in dollars per share) | -0.16 | -0.06 | -0.21 | 0.1 |
| Net loss per common share - diluted (in dollars per share) | -0.16 | -0.06 | -0.21 | 0.1 |
| Weighted-average shares outstanding - basic (in shares) | 200,736,136 | 197,546,239 | 196,127,948 | -98,271,395 |
| Weighted-average shares outstanding - diluted (in shares) | 200,736,136 | 197,546,239 | 196,127,948 | -98,271,395 |
Esperion Therapeutics, Inc. (ESPR)
Esperion Therapeutics, Inc. (ESPR)